Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone
Vaccination against Ebolavirus is an emerging public health tool during Ebola Virus Disease outbreaks. We examined demand issues related to deployment of Ebolavirus vaccine during the 2014–2015 outbreak in Sierra Leone. A cluster survey was administered to a population-based sample in December 2014...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2020-05, Vol.38 (22), p.3854-3861 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3861 |
|---|---|
| container_issue | 22 |
| container_start_page | 3854 |
| container_title | Vaccine |
| container_volume | 38 |
| creator | Jalloh, Mohamed F. Wallace, Aaron S. Bunnell, Rebecca E. Carter, Rosalind J. Redd, John T. Nur, Sophia A. Zeebari, Zangin Ekström, Anna Mia Nordenstedt, Helena |
| description | Vaccination against Ebolavirus is an emerging public health tool during Ebola Virus Disease outbreaks. We examined demand issues related to deployment of Ebolavirus vaccine during the 2014–2015 outbreak in Sierra Leone.
A cluster survey was administered to a population-based sample in December 2014 (N = 3540), before any Ebola vaccine was available to the general public in Sierra Leone. Ebola vaccine demand was captured in this survey by three Likert-scale items that were used to develop a composite score and dichotomized into a binary outcome to define high demand. A multilevel logistic regression model was fitted to assess the associations between perceptions of who should be first to receive an Ebola vaccine and the expression of high demand for an Ebola vaccine.
The largest proportion of respondents reported that health workers (35.1%) or their own families (29.5%) should receive the vaccine first if it became available, rather than politicians (13.8%), vaccination teams (9.8%), or people in high risk areas (8.2%). High demand for an Ebola vaccine was expressed by 74.2% of respondents nationally. The odds of expressing high demand were 13 times greater among those who said they or their families should be the first to take the vaccine compared to those who said politicians should be the first recipients (adjusted odds ratio [aOR] 13.0 [95% confidence interval [CI] 7.8–21.6]). The ultra-brief measure of the Ebola vaccine demand demonstrated acceptable scale reliability (Cronbach’s α = 0.79) and construct validity (single-factor loadings > 0.50).
Perceptions of who should be the first to get the vaccine was associated with high demand for Ebola vaccine around the peak of the outbreak in Sierra Leone. Using an ultra-brief measure of Ebola vaccine demand is a feasible solution in outbreak settings and can help inform development of future rapid assessment tools. |
| doi_str_mv | 10.1016/j.vaccine.2020.03.044 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_472017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X20304230</els_id><sourcerecordid>2425693711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-3f52bf06c42085a76dbb55c4fba6f52263ae4924d8b22838ddd17d97bdb2b66f3</originalsourceid><addsrcrecordid>eNqFksuO0zAUhiMEYsrAI4CM2CChFF_iXFaj0dABpEosuIid5ctJ605iD3YS1GfhZXHUMlAkxMqWz_f_Pvb5s-wpwUuCSfl6t5yk1tbBkmKKl5gtcVHcyxakrlhOOanvZwtMyyIvCP56lj2KcYcx5ow0D7MzRmlDCKaL7MdK-U6io9cFupa97faotSEOz9FqsgacBtQG36MxWrdBEqlgoUU9yDgGQN6hEw9koJfOIOsS6uRgvZMd2voxwtZ3BiXRBHtkxjC7DdvkMA4qgLyZJR8thCDRGryDx9mDVnYRnhzX8-zz9erT1bt8_eHt-6vLda45ZUPOWk5Vi0tdUFxzWZVGKc510SpZphItmYSioYWpFaU1q40xpDJNpYyiqixbdp7lB9_4HW5HJW6D7WXYCy-tOB7dpB2IoqKYVIl_9U_-jf1yKXzYiO1OFHVV8URfHOiE9mA0uCHI7kR0WnF2KzZ-EgTXjJCySQ4vjw7BfxshDqK3UUPXSQfpWwVlDSa8YWxu7cVf6M6PIQ0gUQXlyawiJFH8QOngYwzQ3nVDsJjTJXbiOE0xp0tgJlK6ku7Zn0-5U_2K0--3QhrXlEYporZzgIwNoAdhvP3PFT8BMq_mcg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425693711</pqid></control><display><type>article</type><title>Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>SWEPUB Freely available online</source><source>ProQuest Central UK/Ireland</source><creator>Jalloh, Mohamed F. ; Wallace, Aaron S. ; Bunnell, Rebecca E. ; Carter, Rosalind J. ; Redd, John T. ; Nur, Sophia A. ; Zeebari, Zangin ; Ekström, Anna Mia ; Nordenstedt, Helena</creator><creatorcontrib>Jalloh, Mohamed F. ; Wallace, Aaron S. ; Bunnell, Rebecca E. ; Carter, Rosalind J. ; Redd, John T. ; Nur, Sophia A. ; Zeebari, Zangin ; Ekström, Anna Mia ; Nordenstedt, Helena</creatorcontrib><description>Vaccination against Ebolavirus is an emerging public health tool during Ebola Virus Disease outbreaks. We examined demand issues related to deployment of Ebolavirus vaccine during the 2014–2015 outbreak in Sierra Leone.
A cluster survey was administered to a population-based sample in December 2014 (N = 3540), before any Ebola vaccine was available to the general public in Sierra Leone. Ebola vaccine demand was captured in this survey by three Likert-scale items that were used to develop a composite score and dichotomized into a binary outcome to define high demand. A multilevel logistic regression model was fitted to assess the associations between perceptions of who should be first to receive an Ebola vaccine and the expression of high demand for an Ebola vaccine.
The largest proportion of respondents reported that health workers (35.1%) or their own families (29.5%) should receive the vaccine first if it became available, rather than politicians (13.8%), vaccination teams (9.8%), or people in high risk areas (8.2%). High demand for an Ebola vaccine was expressed by 74.2% of respondents nationally. The odds of expressing high demand were 13 times greater among those who said they or their families should be the first to take the vaccine compared to those who said politicians should be the first recipients (adjusted odds ratio [aOR] 13.0 [95% confidence interval [CI] 7.8–21.6]). The ultra-brief measure of the Ebola vaccine demand demonstrated acceptable scale reliability (Cronbach’s α = 0.79) and construct validity (single-factor loadings > 0.50).
Perceptions of who should be the first to get the vaccine was associated with high demand for Ebola vaccine around the peak of the outbreak in Sierra Leone. Using an ultra-brief measure of Ebola vaccine demand is a feasible solution in outbreak settings and can help inform development of future rapid assessment tools.</description><identifier>ISSN: 0264-410X</identifier><identifier>ISSN: 1873-2518</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2020.03.044</identifier><identifier>PMID: 32291102</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acceptance ; adolescent ; adult ; Assessments ; Confidence intervals ; construct validity ; Demand ; Disease Outbreaks ; Ebola ; Ebola hemorrhagic fever ; Ebola vaccine ; Ebola Vaccines - administration & dosage ; Ebola Vaccines - supply & distribution ; Ebola virus ; Ebolavirus ; Ebolavirus - immunology ; epidemic ; Epidemics ; family ; FDA approval ; female ; health care delivery ; health care need ; health care personnel ; Health Resources - ethics ; health survey ; Hemorrhagic Fever, Ebola - epidemiology ; Hemorrhagic Fever, Ebola - prevention & control ; high risk population ; Households ; human ; Humans ; Immunization ; Licensed products ; Likert scale ; logistic regression analysis ; major clinical study ; male ; Measure ; medical assessment ; Medical personnel ; Outbreaks ; patient selection ; Perceptions ; Polls & surveys ; priority journal ; public figure ; Public health ; Questionnaires ; Regression models ; Reliability ; Reliability aspects ; Reproducibility of Results ; Scale ; Sierra Leone ; Sierra Leone - epidemiology ; Statistical analysis ; Surveys and Questionnaires ; Vaccination ; Vaccination - ethics ; Vaccine ; Vaccines ; Validity ; Viral diseases ; young adult</subject><ispartof>Vaccine, 2020-05, Vol.38 (22), p.3854-3861</ispartof><rights>2020</rights><rights>Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited May 8, 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-3f52bf06c42085a76dbb55c4fba6f52263ae4924d8b22838ddd17d97bdb2b66f3</citedby><cites>FETCH-LOGICAL-c523t-3f52bf06c42085a76dbb55c4fba6f52263ae4924d8b22838ddd17d97bdb2b66f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2425693711?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,551,777,781,882,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32291102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-48775$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:143557614$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Jalloh, Mohamed F.</creatorcontrib><creatorcontrib>Wallace, Aaron S.</creatorcontrib><creatorcontrib>Bunnell, Rebecca E.</creatorcontrib><creatorcontrib>Carter, Rosalind J.</creatorcontrib><creatorcontrib>Redd, John T.</creatorcontrib><creatorcontrib>Nur, Sophia A.</creatorcontrib><creatorcontrib>Zeebari, Zangin</creatorcontrib><creatorcontrib>Ekström, Anna Mia</creatorcontrib><creatorcontrib>Nordenstedt, Helena</creatorcontrib><title>Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Vaccination against Ebolavirus is an emerging public health tool during Ebola Virus Disease outbreaks. We examined demand issues related to deployment of Ebolavirus vaccine during the 2014–2015 outbreak in Sierra Leone.
A cluster survey was administered to a population-based sample in December 2014 (N = 3540), before any Ebola vaccine was available to the general public in Sierra Leone. Ebola vaccine demand was captured in this survey by three Likert-scale items that were used to develop a composite score and dichotomized into a binary outcome to define high demand. A multilevel logistic regression model was fitted to assess the associations between perceptions of who should be first to receive an Ebola vaccine and the expression of high demand for an Ebola vaccine.
The largest proportion of respondents reported that health workers (35.1%) or their own families (29.5%) should receive the vaccine first if it became available, rather than politicians (13.8%), vaccination teams (9.8%), or people in high risk areas (8.2%). High demand for an Ebola vaccine was expressed by 74.2% of respondents nationally. The odds of expressing high demand were 13 times greater among those who said they or their families should be the first to take the vaccine compared to those who said politicians should be the first recipients (adjusted odds ratio [aOR] 13.0 [95% confidence interval [CI] 7.8–21.6]). The ultra-brief measure of the Ebola vaccine demand demonstrated acceptable scale reliability (Cronbach’s α = 0.79) and construct validity (single-factor loadings > 0.50).
Perceptions of who should be the first to get the vaccine was associated with high demand for Ebola vaccine around the peak of the outbreak in Sierra Leone. Using an ultra-brief measure of Ebola vaccine demand is a feasible solution in outbreak settings and can help inform development of future rapid assessment tools.</description><subject>Acceptance</subject><subject>adolescent</subject><subject>adult</subject><subject>Assessments</subject><subject>Confidence intervals</subject><subject>construct validity</subject><subject>Demand</subject><subject>Disease Outbreaks</subject><subject>Ebola</subject><subject>Ebola hemorrhagic fever</subject><subject>Ebola vaccine</subject><subject>Ebola Vaccines - administration & dosage</subject><subject>Ebola Vaccines - supply & distribution</subject><subject>Ebola virus</subject><subject>Ebolavirus</subject><subject>Ebolavirus - immunology</subject><subject>epidemic</subject><subject>Epidemics</subject><subject>family</subject><subject>FDA approval</subject><subject>female</subject><subject>health care delivery</subject><subject>health care need</subject><subject>health care personnel</subject><subject>Health Resources - ethics</subject><subject>health survey</subject><subject>Hemorrhagic Fever, Ebola - epidemiology</subject><subject>Hemorrhagic Fever, Ebola - prevention & control</subject><subject>high risk population</subject><subject>Households</subject><subject>human</subject><subject>Humans</subject><subject>Immunization</subject><subject>Licensed products</subject><subject>Likert scale</subject><subject>logistic regression analysis</subject><subject>major clinical study</subject><subject>male</subject><subject>Measure</subject><subject>medical assessment</subject><subject>Medical personnel</subject><subject>Outbreaks</subject><subject>patient selection</subject><subject>Perceptions</subject><subject>Polls & surveys</subject><subject>priority journal</subject><subject>public figure</subject><subject>Public health</subject><subject>Questionnaires</subject><subject>Regression models</subject><subject>Reliability</subject><subject>Reliability aspects</subject><subject>Reproducibility of Results</subject><subject>Scale</subject><subject>Sierra Leone</subject><subject>Sierra Leone - epidemiology</subject><subject>Statistical analysis</subject><subject>Surveys and Questionnaires</subject><subject>Vaccination</subject><subject>Vaccination - ethics</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Validity</subject><subject>Viral diseases</subject><subject>young adult</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>D8T</sourceid><recordid>eNqFksuO0zAUhiMEYsrAI4CM2CChFF_iXFaj0dABpEosuIid5ctJ605iD3YS1GfhZXHUMlAkxMqWz_f_Pvb5s-wpwUuCSfl6t5yk1tbBkmKKl5gtcVHcyxakrlhOOanvZwtMyyIvCP56lj2KcYcx5ow0D7MzRmlDCKaL7MdK-U6io9cFupa97faotSEOz9FqsgacBtQG36MxWrdBEqlgoUU9yDgGQN6hEw9koJfOIOsS6uRgvZMd2voxwtZ3BiXRBHtkxjC7DdvkMA4qgLyZJR8thCDRGryDx9mDVnYRnhzX8-zz9erT1bt8_eHt-6vLda45ZUPOWk5Vi0tdUFxzWZVGKc510SpZphItmYSioYWpFaU1q40xpDJNpYyiqixbdp7lB9_4HW5HJW6D7WXYCy-tOB7dpB2IoqKYVIl_9U_-jf1yKXzYiO1OFHVV8URfHOiE9mA0uCHI7kR0WnF2KzZ-EgTXjJCySQ4vjw7BfxshDqK3UUPXSQfpWwVlDSa8YWxu7cVf6M6PIQ0gUQXlyawiJFH8QOngYwzQ3nVDsJjTJXbiOE0xp0tgJlK6ku7Zn0-5U_2K0--3QhrXlEYporZzgIwNoAdhvP3PFT8BMq_mcg</recordid><startdate>20200508</startdate><enddate>20200508</enddate><creator>Jalloh, Mohamed F.</creator><creator>Wallace, Aaron S.</creator><creator>Bunnell, Rebecca E.</creator><creator>Carter, Rosalind J.</creator><creator>Redd, John T.</creator><creator>Nur, Sophia A.</creator><creator>Zeebari, Zangin</creator><creator>Ekström, Anna Mia</creator><creator>Nordenstedt, Helena</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8X</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20200508</creationdate><title>Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone</title><author>Jalloh, Mohamed F. ; Wallace, Aaron S. ; Bunnell, Rebecca E. ; Carter, Rosalind J. ; Redd, John T. ; Nur, Sophia A. ; Zeebari, Zangin ; Ekström, Anna Mia ; Nordenstedt, Helena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-3f52bf06c42085a76dbb55c4fba6f52263ae4924d8b22838ddd17d97bdb2b66f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acceptance</topic><topic>adolescent</topic><topic>adult</topic><topic>Assessments</topic><topic>Confidence intervals</topic><topic>construct validity</topic><topic>Demand</topic><topic>Disease Outbreaks</topic><topic>Ebola</topic><topic>Ebola hemorrhagic fever</topic><topic>Ebola vaccine</topic><topic>Ebola Vaccines - administration & dosage</topic><topic>Ebola Vaccines - supply & distribution</topic><topic>Ebola virus</topic><topic>Ebolavirus</topic><topic>Ebolavirus - immunology</topic><topic>epidemic</topic><topic>Epidemics</topic><topic>family</topic><topic>FDA approval</topic><topic>female</topic><topic>health care delivery</topic><topic>health care need</topic><topic>health care personnel</topic><topic>Health Resources - ethics</topic><topic>health survey</topic><topic>Hemorrhagic Fever, Ebola - epidemiology</topic><topic>Hemorrhagic Fever, Ebola - prevention & control</topic><topic>high risk population</topic><topic>Households</topic><topic>human</topic><topic>Humans</topic><topic>Immunization</topic><topic>Licensed products</topic><topic>Likert scale</topic><topic>logistic regression analysis</topic><topic>major clinical study</topic><topic>male</topic><topic>Measure</topic><topic>medical assessment</topic><topic>Medical personnel</topic><topic>Outbreaks</topic><topic>patient selection</topic><topic>Perceptions</topic><topic>Polls & surveys</topic><topic>priority journal</topic><topic>public figure</topic><topic>Public health</topic><topic>Questionnaires</topic><topic>Regression models</topic><topic>Reliability</topic><topic>Reliability aspects</topic><topic>Reproducibility of Results</topic><topic>Scale</topic><topic>Sierra Leone</topic><topic>Sierra Leone - epidemiology</topic><topic>Statistical analysis</topic><topic>Surveys and Questionnaires</topic><topic>Vaccination</topic><topic>Vaccination - ethics</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Validity</topic><topic>Viral diseases</topic><topic>young adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jalloh, Mohamed F.</creatorcontrib><creatorcontrib>Wallace, Aaron S.</creatorcontrib><creatorcontrib>Bunnell, Rebecca E.</creatorcontrib><creatorcontrib>Carter, Rosalind J.</creatorcontrib><creatorcontrib>Redd, John T.</creatorcontrib><creatorcontrib>Nur, Sophia A.</creatorcontrib><creatorcontrib>Zeebari, Zangin</creatorcontrib><creatorcontrib>Ekström, Anna Mia</creatorcontrib><creatorcontrib>Nordenstedt, Helena</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Högskolan i Jönköping</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jalloh, Mohamed F.</au><au>Wallace, Aaron S.</au><au>Bunnell, Rebecca E.</au><au>Carter, Rosalind J.</au><au>Redd, John T.</au><au>Nur, Sophia A.</au><au>Zeebari, Zangin</au><au>Ekström, Anna Mia</au><au>Nordenstedt, Helena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2020-05-08</date><risdate>2020</risdate><volume>38</volume><issue>22</issue><spage>3854</spage><epage>3861</epage><pages>3854-3861</pages><issn>0264-410X</issn><issn>1873-2518</issn><eissn>1873-2518</eissn><abstract>Vaccination against Ebolavirus is an emerging public health tool during Ebola Virus Disease outbreaks. We examined demand issues related to deployment of Ebolavirus vaccine during the 2014–2015 outbreak in Sierra Leone.
A cluster survey was administered to a population-based sample in December 2014 (N = 3540), before any Ebola vaccine was available to the general public in Sierra Leone. Ebola vaccine demand was captured in this survey by three Likert-scale items that were used to develop a composite score and dichotomized into a binary outcome to define high demand. A multilevel logistic regression model was fitted to assess the associations between perceptions of who should be first to receive an Ebola vaccine and the expression of high demand for an Ebola vaccine.
The largest proportion of respondents reported that health workers (35.1%) or their own families (29.5%) should receive the vaccine first if it became available, rather than politicians (13.8%), vaccination teams (9.8%), or people in high risk areas (8.2%). High demand for an Ebola vaccine was expressed by 74.2% of respondents nationally. The odds of expressing high demand were 13 times greater among those who said they or their families should be the first to take the vaccine compared to those who said politicians should be the first recipients (adjusted odds ratio [aOR] 13.0 [95% confidence interval [CI] 7.8–21.6]). The ultra-brief measure of the Ebola vaccine demand demonstrated acceptable scale reliability (Cronbach’s α = 0.79) and construct validity (single-factor loadings > 0.50).
Perceptions of who should be the first to get the vaccine was associated with high demand for Ebola vaccine around the peak of the outbreak in Sierra Leone. Using an ultra-brief measure of Ebola vaccine demand is a feasible solution in outbreak settings and can help inform development of future rapid assessment tools.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>32291102</pmid><doi>10.1016/j.vaccine.2020.03.044</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2020-05, Vol.38 (22), p.3854-3861 |
| issn | 0264-410X 1873-2518 1873-2518 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_472017 |
| source | MEDLINE; Elsevier ScienceDirect Journals; SWEPUB Freely available online; ProQuest Central UK/Ireland |
| subjects | Acceptance adolescent adult Assessments Confidence intervals construct validity Demand Disease Outbreaks Ebola Ebola hemorrhagic fever Ebola vaccine Ebola Vaccines - administration & dosage Ebola Vaccines - supply & distribution Ebola virus Ebolavirus Ebolavirus - immunology epidemic Epidemics family FDA approval female health care delivery health care need health care personnel Health Resources - ethics health survey Hemorrhagic Fever, Ebola - epidemiology Hemorrhagic Fever, Ebola - prevention & control high risk population Households human Humans Immunization Licensed products Likert scale logistic regression analysis major clinical study male Measure medical assessment Medical personnel Outbreaks patient selection Perceptions Polls & surveys priority journal public figure Public health Questionnaires Regression models Reliability Reliability aspects Reproducibility of Results Scale Sierra Leone Sierra Leone - epidemiology Statistical analysis Surveys and Questionnaires Vaccination Vaccination - ethics Vaccine Vaccines Validity Viral diseases young adult |
| title | Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A39%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ebola%20vaccine?%20Family%20first!%20Evidence%20from%20using%20a%20brief%20measure%20on%20Ebola%20vaccine%20demand%20in%20a%20national%20household%20survey%20during%20the%20outbreak%20in%20Sierra%20Leone&rft.jtitle=Vaccine&rft.au=Jalloh,%20Mohamed%20F.&rft.date=2020-05-08&rft.volume=38&rft.issue=22&rft.spage=3854&rft.epage=3861&rft.pages=3854-3861&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2020.03.044&rft_dat=%3Cproquest_swepu%3E2425693711%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425693711&rft_id=info:pmid/32291102&rft_els_id=S0264410X20304230&rfr_iscdi=true |